Benitec Biopharma Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company dedicated to the advancement of novel genetic medicines. Headquartered in Hayward, California, the company focuses on developing therapies for chronic and life-threatening human conditions. Its core mission revolves around leveraging its proprietary gene silencing technology to address diseases with limited or no effective treatment options.

The company's key technology is the DNA-directed RNA interference (ddRNAi) platform, also known as "Silence and Replace." This innovative platform combines RNA interference with gene therapy to facilitate the sustained silencing of disease-causing genes and the concomitant delivery of wildtype replacement genes following a single administration. Benitec Biopharma's primary therapeutic candidate, BB-301, is currently in development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The company also conducts research in other areas, including Hepatitis B.

In recent news, Benitec Biopharma has been active in investor and scientific communities. The company participated in the Citizens JMP Life Science Conference in May 2024, and was scheduled to attend the Piper Sandler Annual Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit in December 2024. Jerel Banks, MD, PhD, serves as the Executive Chairman and Chief Executive Officer. The company also presented interim Phase 1b/2a clinical study results for BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting, highlighting continued durable improvements for the low dose of the therapeutic.